Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel

Table 5 Frequency of mental health resource use per patient with NDM per year in the UK

Mental health resource	BSC – Mean number of annual visits (range)	Mexiletine – Mean number of annual visits (range)	Difference (%)	BSC:mexiletine ratio^a
Neuropsychologist	0 (0-0)	0 (0-0)	0	1
General practitioner (mental health-related visits)	7.25 (0-20)	5.25 (0-12)	-2	1.4
Psychiatrist	0.5 (0-2)	0.5 (0-2)	0	1
Psychologist	4 (0-10)	3 (0-6)	-1	1.3

Four experts completed this question in RD2, one expert dropped-out
Key: BSC Best supportive care (defined as any supportive care that symptomatic adult patients with NDM may receive that does not involve symptom-modifying pharmacological treatment; includes, for example, the use of supportive medication [e.g. pain killers], mobility aids, physiotherapy or speech therapy), HRU Healthcare resource utilization
^aThe ratio was calculated by dividing the mean proportion number of annual visits of patients receiving BSC that require a resource by the mean proportion number of annual visits of patients treated with mexiletine (NaMuscla) that require the resource